$238.05
+1.08 (+0.46%)
Last updated: Jul 15, 2026 07:03
Fundamentals Overview
Jazz Pharmaceuticals plc is near the high of its 52-week range with premium valuation, trading relatively flat today.
Valuation premium
Intrinsic value (DCF)
+77.9% upside vs price
Profitability
Risk (Beta)
0.32 — lower vol
Earnings & growth
BullzEye Analysis
Our composite tilts Buy on technicals (e.g. RSI, ADX, trend), fundamentals, sentiment, sector and index context, and risk.
Composite Signal
Supporting (Buy):
DCF +77.9% upside vs price · Analyst grade: B- · 3M vs S&P 500: +12.3% · 3M vs Healthcare sector: +14.9%
Not financial advice. For education and research only; do your own research and consider a financial advisor before investing.
Key Stats
About
Ratings & Grades at a Glance
Overall rating: B-. Recent institutional grades: mixed. Current institutional positions: Buy: 9, Neutral: 1, Outperform: 6, Overweight: 14.
Valuation & Ratios
Valuation, liquidity, and profitability metrics are consolidated here (including ratios that previously appeared in the Financials story). Trailing (TTM) vs forward-looking (e.g. DCF) is noted on each line where it matters.
DCF vs price: DCF estimate is $423.54; current price is $238.05. That’s a +77.9% gap. When the gap is large (e.g. >20%), that’s divergence; when they’re close, that’s convergence. Differences can reflect growth expectations, sector premiums, or conservative vs. optimistic assumptions. Use DCF as one input alongside technicals and sentiment.
| Metric | Value |
|---|---|
| Valuation | |
| P/E (TTM) | 533.52 |
| DCF value (model) | $423.54 (77.9% upside) |
| PEG (TTM) | N/A |
| P/B (TTM) | 3.25 |
| P/S (TTM) | 3.37 |
| P/FCF (TTM) | 12.01 |
| Liquidity & enterprise | |
| Current Ratio (TTM) | 2.04 |
| Quick Ratio (TTM) | 1.85 |
| Cash Ratio (TTM) | 0.82 |
| Profitability | |
| ROE (TTM) | N/A |
| ROA (TTM) | N/A |
| Revenue growth (YoY) | N/A |
| Net margin (TTM) | 0.66% |
| Gross margin (TTM) | 84.12% |
| Operating margin (TTM) | 11.13% |
| Debt to equity (TTM) | N/A |
Latest News
News loads when you open this tab.
Price Target, Ratings & Grades
Analyst price targets, consensus, rating snapshot, and institutional grades for JAZZ.
Analyst Sentiment at a Glance
Stock Grades (Institutions)
| Institution | Action | Previous Grade | New Grade | Date |
|---|---|---|---|---|
| Deutsche Bank | maintain | Buy | Buy | 2026-07-09 |
| Truist Securities | maintain | Buy | Buy | 2026-07-07 |
| B of A Securities | maintain | Buy | Buy | 2026-06-10 |
| Barclays | maintain | Overweight | Overweight | 2026-05-27 |
| Piper Sandler | maintain | Overweight | Overweight | 2026-05-22 |
| UBS | upgrade | Neutral | Buy | 2026-05-19 |
| TD Cowen | maintain | Buy | Buy | 2026-05-06 |
| RBC Capital | maintain | Outperform | Outperform | 2026-05-06 |
| Barclays | maintain | Overweight | Overweight | 2026-05-06 |
| Wells Fargo | maintain | Overweight | Overweight | 2026-05-06 |
| Leerink Partners | maintain | Outperform | Outperform | 2026-04-22 |
| Barclays | maintain | Overweight | Overweight | 2026-04-20 |
| Piper Sandler | maintain | Overweight | Overweight | 2026-03-19 |
| B of A Securities | maintain | Buy | Buy | 2026-02-25 |
| RBC Capital | maintain | Outperform | Outperform | 2026-02-25 |
| Wells Fargo | maintain | Overweight | Overweight | 2026-02-25 |
| Morgan Stanley | maintain | Overweight | Overweight | 2026-02-25 |
| Needham | maintain | Buy | Buy | 2026-01-12 |
| Truist Securities | maintain | Buy | Buy | 2026-01-12 |
| Piper Sandler | maintain | Overweight | Overweight | 2025-12-10 |
| UBS | downgrade | Buy | Neutral | 2025-11-24 |
| Baird | maintain | Outperform | Outperform | 2025-11-18 |
| B of A Securities | maintain | Buy | Buy | 2025-11-18 |
| Wells Fargo | maintain | Overweight | Overweight | 2025-11-18 |
| Morgan Stanley | maintain | Overweight | Overweight | 2025-11-17 |
| RBC Capital | maintain | Outperform | Outperform | 2025-11-17 |
| RBC Capital | maintain | Outperform | Outperform | 2025-11-06 |
| JP Morgan | maintain | Overweight | Overweight | 2025-10-27 |
| Morgan Stanley | maintain | Overweight | Overweight | 2025-10-20 |
| Morgan Stanley | maintain | Overweight | Overweight | 2025-09-24 |